+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Japan Proton Therapy Market, Share, Forecast 2022-2027, Industry Trends, Growth, Size, Impact of COVID-19, Company Analysis

  • ID: 5521695
  • Report
  • January 2022
  • Region: Japan
  • 130 Pages
  • Renub Research

FEATURED COMPANIES

  • Elekta
  • IBA Proton Therapy
  • Varian Medical Systems
Japan Proton Therapy Market Potential will be US$ 8.6 Billion by 2027. Over the years, various techniques for cancer treatment have emerged, such as chemotherapy, surgery, and proton therapy. The proton therapy is the new technology and is expected to least impair the quality of life compared to other forms of treatment. Japan has one of the highest numbers of proton therapy treatment clinics globally. The improving cutting-edge technology in radiotherapy and growing technological development in Japan will further drive the Japan proton therapy industry in the future.



COVID-19 Impact on Japan Proton Therapy Industry


Despite the outbreak of COVID-19 worldwide, the proton therapy market has grown at a constant rate. Proton therapy's radiation therapy was stopped for a brief round period, but it was resumed for patients. In addition, to take care of the regular patient and radiation therapies patients in Japan, many processes have been finalized to help the patients with therapies; as such many implementations and algorithms have been carried out to safeguard the radiation patients from COVID-19.

Japan Proton Therapy Potential Market Size was US$ 6.1 Billion post-pandemic recoveries in 2021


The growth of the proton therapy market in Japan is mainly driven by rising healthcare expenditure, expanding preference for advanced therapies by healthcare practitioners, increasing confirmation, and increasing cancer pervasiveness. Another outstanding growth driver is the faster uptake and access and premium pricing. As these systems become more widespread, they are likely to require further refinement and enhancement to respond to the needs of medical staff.

Cancer Types - Market Segmentation


Based on Cancer Types, the proton therapy market of Japan is further segmented into Central Nervous System (CNS) Tumors, Head and Neck Cancer, Lung Cancer, GI (Gastro-Intestinal) Cancer, Hepatocellular Carcinoma (HCC) Cancer, Pancreas Cancer, Gynecologic Cancers, Prostate Cancer, Bone, and Soft Tissue Cancer and Other Cancer. According to the publisher report, Japan Proton Therapy Industry is expected to grow with a CAGR of 5.9% during 2021-2027.

Besides, proton therapy applications are more inclined towards Gastrointestinal Tract Cancer and lung cancer due to references by healthcare specialists. Moreover, proton therapy is also recognized to be comparatively safer in the case of patients with central nervous system (CNS) tumors.

Although there is less experience with proton therapy combined with chemotherapy for pancreatic cancer, favorable outcomes have been reported recently in Japan. Remarkably, these applications are anticipated to drive the revenue for the proton therapy industry over the forecast period.

Competitive Landscape


Companies existing in the Japan Proton Therapy Market are trying to create their mark by adopting new technologies at an accelerated rate. The company has also tried to enrich its product catalogs through product developments. Also, companies have acquired small companies to resolve the potential resource gap that prevailed in their technologies and products. The major players of the Japan Proton Therapy Market studied in the report are IBA Proton Therapy, Varian Medical Systems, and Elekta.

This report "Japan Proton Therapy Market, Patients by 10 Cancer Types (Central Nervous System (CNS), Head and Neck, Lung, GI (Gastro-Intestinal), Hepatocellular Carcinoma (HCC), Pancreas, Gynecologic, Prostate, Bone and Soft Tissue, Others), Companies (IBA Proton Therapy, Varian Medical Systems, Elekta)" Reimbursement Policies & Persons Treated at Centers provides a comprehensive assessment of the fast-evolving, high-growth of Japan Proton Therapy Market.

Cancer Types - Japan Proton Therapy Number of Patients have been covered from 10 viewpoints:


1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer

Cancer Types - Japan Proton Therapy Market have been covered from 10 viewpoints:


1. Central Nervous System (CNS) Tumors
2. Head and Neck Cancer
3. Lung Cancer
4. GI (Gastro-Intestinal) Cancer
5. Hepatocellular Carcinoma (HCC) Cancer
6. Pancreas Cancer
7. Gynecologic Cancers
8. Prostate Cancer
9. Bone and Soft Tissue Cancer
10. Others Cancer

All companies have been covered from 3 viewpoints:

  • Overview
  • Recent Developments
  • Sales Analysis

Companies Covered:


1. IBA Proton Therapy
2. Varian Medical Systems
3. Elekta
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Elekta
  • IBA Proton Therapy
  • Varian Medical Systems
1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges

5. Japan Proton Therapy Market (Actual & Untapped)
5.1 Actual Proton Therapy Market
5.2 Untapped Proton Therapy Market

6. Number of Patients - Japan Proton Therapy
6.1 Actual Numbers
6.2 Untapped Numbers

7. Cancer Types - Japan Proton Therapy Number of Patients
7.1 Central Nervous System (CNS) Tumors
7.2 Head and Neck Cancer
7.3 Lung Cancer
7.4 GI (Gastro-Intestinal) Cancer
7.5 Hepatocellular Carcinoma (HCC) Cancer
7.6 Pancreas Cancer
7.7 Gynecologic Cancers
7.8 Prostate Cancer
7.9 Bone and Soft Tissue Cancer
7.10 Others Cancer

8. Cancer Types - Japan Proton Therapy Market
8.1 Central Nervous System (CNS) Tumors
8.2 Head and Neck Cancer
8.3 Lung Cancer
8.4 GI (Gastro-Intestinal) Cancer
8.5 Hepatocellular Carcinoma (HCC) Cancer
8.6 Pancreas Cancer
8.7 Gynecologic Cancers
8.8 Prostate Cancer
8.9 Bone and Soft Tissue Cancer
8.10 Others Cancer

9. Japan - List of Proton Therapy Centers
9.1 Operating Proton Therapy Centers
9.2 Under-Construction Therapy Centers

10. Reimbursement Policies - Japan Proton Therapy

11. Components of a Standard Proton Therapy Center
11.1 Type of Proton Accelerator
11.1.1 Synchrotrons (example: LLUMC at Loma Linda)
11.1.2 Cyclotrons (example: MGH Boston)
11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
11.1.4 Linacs (Rome)
11.1.5 H-minus Synchrotrons
11.1.6 Separated Sector Cyclotrons
11.1.7 Super-conducting Cyclotrons
11.1.8 Fast Cycling Synchrotron
11.2 Beam Transport System
11.3 Beam Delivery System
11.3.1 The Passive Scattering Technique
11.3.2 Beam Scanning
11.4 Type of Nozzle
11.4.1 Single Scattering
11.4.2 Double Scattering
11.4.3 Uniform Scanning Nozzle
11.4.4 Pencil Scanning Nozzle
11.5 Treatment Planning System
11.6 Image Viewers
11.7 Patient Positioning System (PPS)
11.8 Human Resource

12. Porters Five Forces
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13. Company Analysis
13.1 IBA Proton Therapy
13.1.1 Overview
13.1.2 Recent Development
13.1.3 Sales Analysis
13.2 Varian Medical Systems
13.2.1 Overview
13.2.2 Recent Development
13.2.3 Sales Analysis
13.3 Elekta
13.3.1 Overview
13.3.2 Recent Development
13.3.3 Sales Analysis

List of Figures:
Figure-01: Japan - Actual Proton Therapy Market (Million US$), 2016 - 2021
Figure-02: Japan - Forecast for Actual Proton Therapy Market (Million US$), 2022 - 2027
Figure-03: Japan - Untapped Proton Therapy Market (Million US$), 2016 - 2021
Figure-04: Japan - Forecast for Untapped Proton Therapy Market (Million US$), 2022 - 2027
Figure-05: Japan - Actual Numbers (Number), 2016 - 2021
Figure-06: Japan - Forecast for Actual Numbers (Number), 2022 - 2027
Figure-07: Japan - Untapped Numbers (Number), 2016 - 2021
Figure-08: Japan - Forecast for Untapped Numbers (Number), 2022 - 2027
Figure-09: Japan - Central Nervous System (CNS) Tumors Patients (Number), 2016 - 2021
Figure-10: Japan - Forecast for Central Nervous System (CNS) Tumors Patients (Number), 2022 - 2027
Figure-11: Japan - Head and Neck Cancer Patients (Number), 2016 - 2021
Figure-12: Japan - Forecast for Head and Neck Cancer Patients (Number), 2022 - 2027
Figure-13: Japan - Lung Cancer Patients (Number), 2016 - 2021
Figure-14: Japan - Forecast for Lung Cancer Patients (Number), 2022 - 2027
Figure-15: Japan - GI (Gastro-Intestinal) Cancer Patients (Number), 2016 - 2021
Figure-16: Japan - Forecast for GI (Gastro-Intestinal) Cancer Patients (Number), 2022 - 2027
Figure-17: Japan - Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2016 - 2021
Figure-18: Japan - Forecast for Hepatocellular Carcinoma (HCC) Cancer Patients (Number), 2022 - 2027
Figure-19: Japan - Pancreas Cancer Patients (Number), 2016 - 2021
Figure-20: Japan - Forecast for Pancreas Cancer Patients (Number), 2022 - 2027
Figure-21: Japan - Gynecologic Cancers Patients (Number), 2016 - 2021
Figure-22: Japan - Forecast for Gynecologic Cancers Patients (Number), 2022 - 2027
Figure-23: Japan - Prostate Cancer Patients (Number), 2016 - 2021
Figure-24: Japan - Forecast for Prostate Cancer Patients (Number), 2022 - 2027
Figure-25: Japan - Bone and Soft Tissue Cancer Patients (Number), 2016 - 2021
Figure-26: Japan - Forecast for Bone and Soft Tissue Cancer Patients (Number), 2022 - 2027
Figure-27: Japan - Others Cancer Patients (Number), 2016 - 2021
Figure-28: Japan - Forecast for Others Cancer Patients (Number), 2022 - 2027
Figure-29: Japan - Central Nervous System (CNS) Tumors Market (Million US$), 2016 - 2021
Figure-30: Japan - Forecast for Central Nervous System (CNS) Tumors Market (Million US$), 2022 - 2027
Figure-31: Japan - Head and Neck Cancer Market (Million US$), 2016 - 2021
Figure-32: Japan - Forecast for Head and Neck Cancer Market (Million US$), 2022 - 2027
Figure-33: Japan - Lung Cancer Market (Million US$), 2016 - 2021
Figure-34: Japan - Forecast for Lung Cancer Market (Million US$), 2022 - 2027
Figure-35: Japan - GI (Gastro-Intestinal) Cancer Market (Million US$), 2016 - 2021
Figure-36: Japan - Forecast for GI (Gastro-Intestinal) Cancer Market (Million US$), 2022 - 2027
Figure-37: Japan - Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2016 - 2021
Figure-38: Japan - Forecast for Hepatocellular Carcinoma (HCC) Cancer Market (Million US$), 2022 - 2027
Figure-39: Japan - Pancreas Cancer Market (Million US$), 2016 - 2021
Figure-40: Japan - Forecast for Pancreas Cancer Market (Million US$), 2022 - 2027
Figure-41: Japan - Gynecologic Cancers Market (Million US$), 2016 - 2021
Figure-42: Japan - Forecast for Gynecologic Cancers Market (Million US$), 2022 - 2027
Figure-43: Japan - Prostate Cancer Market (Million US$), 2016 - 2021
Figure-44: Japan - Forecast for Prostate Cancer Market (Million US$), 2022 - 2027
Figure-45: Japan - Bone and Soft Tissue Cancer Market (Million US$), 2016 - 2021
Figure-46: Japan - Forecast for Bone and Soft Tissue Cancer Market (Million US$), 2022 - 2027
Figure-47: Japan - Others Cancer Market (Million US$), 2016 - 2021
Figure-48: Japan - Forecast for Others Cancer Market (Million US$), 2022 - 2027
Figure-49: IBA Proton Therapy - Global Revenue (Million US$), 2016 - 2021
Figure-50: IBA Proton Therapy - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-51: Varian Medical Systems - Global Revenue (Million US$), 2016 - 2021
Figure-52: Varian Medical Systems - Forecast for Global Revenue (Million US$), 2022 - 2027
Figure-53: Elekta - Global Revenue (Million US$), 2016 - 2021
Figure-54: Elekta - Forecast for Global Revenue (Million US$), 2022 - 2027

List of Tables:
Table-1: Japan - Proton Therapy Centers in Operation
Table-2: Japan - Proton Therapy Centers in Under-Construction
Note: Product cover images may vary from those shown
  • IBA Proton Therapy
  • Varian Medical Systems
  • Elekta
Note: Product cover images may vary from those shown

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...